Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EJ3B
|
|||
| Former ID |
DNCL002367
|
|||
| Drug Name |
AMG 900
|
|||
| Synonyms |
AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Company |
Amgen Thousand
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H21N7OS
|
|||
| Canonical SMILES |
CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N
|
|||
| InChI |
1S/C28H21N7OS/c1-17-15-24(37-16-17)25-20-5-2-3-6-21(20)26(35-34-25)32-18-8-10-19(11-9-18)36-27-22(7-4-13-30-27)23-12-14-31-28(29)33-23/h2-16H,1H3,(H,32,35)(H2,29,31,33)
|
|||
| InChIKey |
IVUGFMLRJOCGAS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 945595-80-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
50085297, 57153227, 123055443, 135727848, 136340314, 136367484, 137275938, 138171610, 144115599, 152258491, 160647326, 162011353, 162038106, 162202641, 163642970, 164193995, 172095415, 174531643, 185969977, 189622853, 198981726, 223705215, 224563073, 226817947, 242060341, 242559915, 245945322, 249565740, 251962962, 252110169, 252160447, 252214714
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8060). | |||
| REF 2 | Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.